Mesothelin-car-hmscs with pd-1/tgf-β inhibition for solid tumor therapy

Overview

This novel approach utilizes mesothelin (M)-CAR-human mesenchymal stem cells (hMSCs) engineered to address the significant challenges of solid tumor therapy. By inhibiting PD-1 and TGF-β signaling pathways, these hMSCs are designed to effectively infiltrate tumors, resist exhaustion, and overcome immunosuppressive tumor microenvironments. The solution focuses on treating solid tumors like ovarian cancer, where traditional M-CAR T cells face limitations due to stromal obstruction and tumor microenvironment-induced exhaustion.

Technical specifications

Key innovations include:

• Tumor-homing hMSCs: Engineered with TGF-β receptor knockout and truncated PD-1, enhancing tumor infiltration.
• Optimized CAR design: Utilizes neural network-optimized costimulatory domains and exhaustion-resistant activation domains.
• Shed-M-resistant scFv: Overcomes inhibition by tumor-shed antigens and minimizes fratricide.
• Exosome secretion: Enhances tumor infiltration through CAR-exosome production.
• Validation methods: Tested using high-throughput microfluidic models simulating the tumor microenvironment, replacing traditional animal models.

Technology readiness level

Currently at TRL 4, the technology has undergone validation in controlled environments, specifically within microfluidic models that mimic the ovarian tumor microenvironment. Further development will focus on refining the CAR-hMSC platform through advanced genetic modifications and validating their efficacy in more comprehensive in vitro settings.